Core Insights - Eli Lilly and Company announced promising Phase 1 data for its folate receptor alpha (FRα) antibody-drug conjugate (ADC) LY4170156, showing a preliminary overall objective response rate (ORR) of 55% in women with heavily pre-treated platinum-resistant ovarian cancer [1][2][3] Group 1: Clinical Data and Efficacy - The study enrolled 95 participants with high-grade serous ovarian cancer, with a median of five prior systemic regimens [2][3] - Among the 95 patients, 51% had tumors with FRα expression less than 75%, while 34% had expression of 75% or higher [2] - The ORR was 45% in 58 efficacy-evaluable patients, with a disease control rate of 74% [3] Group 2: Safety Profile - The most common treatment-emergent adverse events included nausea (64%), anemia (40%), fatigue (32%), vomiting (32%), diarrhea (28%), and neutropenia (27%) [3] - No maximum tolerated dose has been established, and treatment-emergent neuropathy and ocular toxicity have not been observed to date [3] Group 3: Future Directions - Based on the results, the company aims to advance LY4170156 into registrational Phase 3 clinical trials [4] - The ADC is designed to target FRα across expression levels with an improved therapeutic index, potentially benefiting a larger number of ovarian cancer patients [5]

Core Insights - Eli Lilly and Company is set to present data on several investigational drugs at the 2025 ASCO Annual Meeting, including imlunestrant, olomorasib, LY4170156, and Verzenio [1] Group 1: Imlunestrant (Investigational Oral SERD) - The company will present patient-reported outcomes from the Phase 3 EMBER-3 trial for patients with ER+, HER2- advanced breast cancer [2] - Expanded safety analyses from the EMBER-3 trial will also be featured in a poster presentation [2] Group 2: Olomorasib (Investigational KRAS G12C Inhibitor) - Updated results from a Phase 1/2 study of olomorasib will be reported, showing preliminary evidence of CNS activity in combination with pembrolizumab for KRAS G12C-mutant advanced NSCLC and with cetuximab for KRAS G12C-mutant colorectal cancer [3] - The presentations will utilize data cut-off dates of January 15, 2025, and November 13, 2024 [3] Group 3: LY4170156 (Investigational ADC Targeting FRα) - Initial results from a Phase 1a/1b study of LY4170156 in patients with platinum-resistant ovarian cancer will be presented [4] - The study involves a humanized monoclonal antibody linked to a topoisomerase I inhibitor [4] Group 4: Verzenio (Abemaciclib) - The impact of body mass index (BMI) on the efficacy and safety of Verzenio in breast cancer patients will be discussed [8] - Verzenio is an approved treatment for certain HR+, HER2- breast cancers and is available in multiple strengths [12][13]